COFG Advisors LLC Invests $4.09 Million in AbbVie Inc. $ABBV

Posted by Stanley Muller on Jun 3rd, 2026

COFG Advisors LLC acquired a new position in AbbVie Inc. (NYSE:ABBV – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 17,902 shares of the company’s stock, valued at approximately $4,090,000. AbbVie comprises 1.0% of COFG Advisors LLC’s portfolio, making the stock its 17th biggest position.

Other hedge funds have also recently made changes to their positions in the company. Chelsea Counsel Co. bought a new stake in shares of AbbVie in the 3rd quarter worth approximately $26,000. Westend Capital Management LLC bought a new stake in shares of AbbVie in the 4th quarter worth approximately $29,000. Texas Capital Bancshares Inc TX bought a new stake in shares of AbbVie in the 3rd quarter worth approximately $31,000. Legacy Wealth Managment LLC ID lifted its holdings in shares of AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after acquiring an additional 73 shares during the last quarter. Finally, WestEnd Advisors LLC lifted its holdings in shares of AbbVie by 160.4% in the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock worth $32,000 after acquiring an additional 85 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ABBV has been the subject of a number of recent research reports. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. William Blair reaffirmed an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Guggenheim reaffirmed a “buy” rating and issued a $249.00 target price on shares of AbbVie in a research note on Friday, May 1st. Piper Sandler lifted their target price on shares of AbbVie from $294.00 to $298.00 and gave the stock an “overweight” rating in a research note on Thursday, May 14th. Finally, Bank of America raised shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 target price on the stock in a research note on Thursday, April 30th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $253.43.

Get Our Latest Stock Analysis on AbbVie

AbbVie Trading Down 2.3%

Shares of AbbVie stock opened at $212.63 on Tuesday. The company’s fifty day simple moving average is $208.56 and its two-hundred day simple moving average is $219.58. The company has a market cap of $375.67 billion, a P/E ratio of 104.74, a PEG ratio of 0.75 and a beta of 0.32. AbbVie Inc. has a 12-month low of $181.73 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. The business had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.46 EPS. Analysts predict that AbbVie Inc. will post 14.3 EPS for the current fiscal year.

Insider Transactions at AbbVie

In other news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.06% of the company’s stock.

About AbbVie

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.